mounjaro retatrutide Retatrutide: The New Triple-Agonist Weight Loss Treatment ๐ First Day on Retatrutide!
Description
Victoza a GLP-1 for diabetes is expected to lose patent protection in 2024
However, research is lacking comparing the benefits of combining the two to enhance metabolic benefits
[DOI] [PMC free article] [PubMed] [Google Scholar] 186
The dual mechanism does not appear to reduce the gastroparesis risk
These GI effects are typically temporary and most common during the first 4 to 8 weeks of treatment and often resolve as the body adjusts
